3 results
Approved WMOPending
The primary objective of this study is to investigate whether differences in patient specific pharmacokinetic properties, both dynamic and absolute, reveal the difference in response to lithium treatment. The pharmacokinetic properties which will be…
Approved WMORecruiting
To test the hypothesis that LY3314814, administered orally at doses of 20 and 50 mg daily for 78 weeks, will slow the decline of AD ascompared with placebo in patients with mild AD dementia.
Approved WMORecruiting
To determine the minimum number of CESB-guided tissue samples needed to establish a final histopathological biopsy diagnosis for ROLs.